All data underlying the findings in this study are freely available in this manuscript and its supplemental file. The sequencing data are publically available in the following links: <http://dx.doi.org/10.7910/DVN/C85WNZ> and <https://hive.biochemistry.gwu.edu/dna.cgi?cmd=home&folder=/HIVE> Space/California 2009 pandemic vaccine.

Introduction {#sec001}
============

The influenza A/California/07/2009 (H1N1) virus emerged in Mexico, and was identified in the United States at the beginning of 2009. It caused outbreaks of respiratory illness in Mexico and in the United States, \[[@pone.0138650.ref001]\] and was shown to be genetically related to swine influenza viruses \[[@pone.0138650.ref002]\]. Subsequently, the virus spread to several other countries in North America, and eventually the outbreak reached pandemic proportions, which was recognized by the World Health Organization (WHO) in June of 2009 \[[@pone.0138650.ref003], [@pone.0138650.ref004]\].

The quick emergence and spread of A/California/07/2009 (H1N1) virus has been of great concern globally. Therefore, the development of A /California/07/2009 vaccine was an essential component of the global preventive strategy for the pandemic preparedness and response. WHO recommended that pandemic influenza A (H1N1) vaccines must contain A/California/7/2009 (H1N1)-like virus \[[@pone.0138650.ref005]\].

To date, several vaccines have been developed against A/California/07/2009 (H1N1) virus. Some vaccine viruses were prepared by classical reassortment (e.g. X-179A and X-181); others by reverse genetics (e.g. 121XP). They were manufactured as seasonal influenza vaccines manufactured i.e. after virus cultivation; the allantoic fluid of the egg is harvested and is then usually clarified by centrifugation to remove cellular debris. Then whole virus subjected to purification, concentration, and inactivation steps.---See more detail at: <http://www.ifpma.org/resources/influenza-vaccines/influenza-vaccines/vaccine-manufacture-virus-processing.html#sthash.5GUYGsGs.dpuf>.

The A/California/07/2009 (H1N1) strain is an influenza A virus, a single-stranded RNA virus from *Orthomyxoviridae* family \[[@pone.0138650.ref006]\]. The family contains four other species: influenza B virus, influenza C virus, thogotovirus and isavirus. The genome of influenza A virus consists of eight negative-sense RNA segments that encode at least 10 proteins. Influenza A virus genome is highly variable due to low fidelity of RNA polymerase and reassortment between co-infecting strains \[[@pone.0138650.ref007]\]. New virus mutants emerge continuously, allowing viruses to evade host immunity and cause cyclical annual outbreaks, and occasionally pandemics.

Spontaneous mutations easily emerge in RNA viruses, and the consequences of their accumulation must be identified to ensure the safety and potency of vaccines. The genetic diversity within a viral population is important, as RNA viruses in particular have high mutation rates, can evolve rapidly, and may exhibit adaptation to specific hosts and/or tissues \[[@pone.0138650.ref008]\]. Because of the genetic and antigenic plasticity, influenza vaccines have to be reformulated frequently to include antigens of the dominant circulating strains. Most live and inactivated influenza vaccines are produced by reassortment of the current strains with high-growth reference strains, to enable high yields in eggs or cell substrates used for vaccine production \[[@pone.0138650.ref009], [@pone.0138650.ref010]\]. Adaptation to growth in different cells can lead to changes in the viral receptor-binding region, as well as in protective epitopes, because they significantly overlap each other \[[@pone.0138650.ref011], [@pone.0138650.ref012]\]. Therefore, it is important to monitor genetic changes of viruses used in vaccine manufacture to ensure that their antigenic structures remain intact.

Most mutants are present in viral populations at relatively low levels, making them difficult to detect using conventional sequencing methods. A highly sensitive mutant analysis by PCR and restriction enzyme cleavage (MAPREC) \[[@pone.0138650.ref013], [@pone.0138650.ref014]\] and quantitative allele-specific PCR (asqPCR) \[[@pone.0138650.ref015]\] were developed for detection of a low level of mutants in viral vaccines. However, these methods are only suitable for analysis of one mutation at a time, and cannot be used to screen for unknown mutations.

Other approaches based on analysis of electrophoretic mobility in gels \[[@pone.0138650.ref016], [@pone.0138650.ref017]\] do not always allow precise location of mutations. Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF), mass spectrometry \[[@pone.0138650.ref018]\], and hybridization with microarrays of short oligonucleotides \[[@pone.0138650.ref019]--[@pone.0138650.ref021]\] are sensitive, but are relatively laborious and may require follow-up by direct sequencing.

Recently, several versions of high-throughput sequencing technology, known also as deep or massively parallel sequencing (MPS), enabled rapid generation of large amounts of sequence information \[[@pone.0138650.ref022]\]. These new technologies were shown to be suitable for analysis of heterogeneities in viral populations \[[@pone.0138650.ref023]\]. Previously, we have demonstrated that MPS can be used to monitor genetic stability of Oral Polio Vaccines (OPV) \[[@pone.0138650.ref024]\], and could replace the WHO-recommended MAPREC assay for lot release of OPV. In this study, Illumina sequencing technology was used for screening mutations in viruses of A/California/07/2009 (H1N1) vaccine strains passaged in eggs. We found that this approach could be used to identify and to accurately quantify small amounts of mutant viruses present in preparations of inactivated influenza vaccines. We also found that sequence heterogeneity of seed viruses depended on the methods used for their preparation. The ability to quantify potentially undesirable mutations in vaccine batches makes this method suitable for quality control to ensure manufacture of safe and effective vaccines.

Materials and Methods {#sec002}
=====================

Viruses and reference sequences

Viruses X-179A, X-181 and 121XP were passaged in eggs under similar conditions to those of the manufacturers \[[@pone.0138650.ref025], [@pone.0138650.ref026]\], and A/Puerto Rico/08/34 (H1N1) reference and A/California/07/2009 (H1N1) pandemic virus stocks ([Table 1](#pone.0138650.t001){ref-type="table"}), obtained from the strain collection at the Center for Biologics Evaluation and Research, US Food and Drug Administration were grown in eggs. All these viruses ([Table 1](#pone.0138650.t001){ref-type="table"}) were propagated in 10 days old embryonated hen's eggs by inoculation of 0.2 ml of diluted virus stock containing about 10^4^ pfu at 33°C. Allantoic fluid was harvested at 72 hours post infection and clarified by spinning at 4000 rpm for 10 min at 4°C. The clarified viruses were saved at -80°C.

10.1371/journal.pone.0138650.t001

###### Viruses of A/California/07/2009 vaccines, and A/PR/8/34 and wild type A/California/07/2009 viruses used for deep sequencing analysis.

Note: CBER: Center for Biologics Evaluation and Research at US Food and Drug Administration.

![](pone.0138650.t001){#pone.0138650.t001g}

  Sample code                                        Reference and Derivation   Number of passages on eggs
  -------------------------------------------------- -------------------------- ----------------------------
  X-181                                              X-181                      1
  X-181-M1                                           X-181                      9
  X-181-M2                                           X-181                      9
  X181-M3                                            X-181                      13
  X-181-M4                                           X-181                      10
  X-179A                                             X-179A                     1
  X-179A-M1                                          X-179A                     10
  X-179A-M2                                          X-179A                     11
  X-179A-M3                                          X-179A                     12
  X-179A-M4                                          X-179A                     11
  X-179A-M5                                          X-179A                     13
  121XP-M4                                           121XP                      10
  A/Ca/07/2009                                       A/California/07/2009       1
  A/PR/8/34 (CBER)                                   A/Puerto Rico/08/34        1
  A/PR/8/34-1[\*](#t001fn001){ref-type="table-fn"}   A/Puerto Rico/08/34        14
  A/PR/8/34-3[\*](#t001fn001){ref-type="table-fn"}   A/Puerto Rico/08/34        14

\*: A/PR/8/34 virus stock was passaged 13 times in eggs, and the last passaged virus was passaged one time (passage 14) separately in 2 different eggs, the 2 harvested viruses are designated as A/PR/8/34-1 and A/PR/8/34-3.

Amplification of the entire influenza virus genome {#sec003}
--------------------------------------------------

Total RNA was isolated from 140 μl of virus suspension using QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. The RNA was eluted in a final volume of 60 μl of sterile RNase-free water. cDNA was synthesized using Superscript III Reverse Transcriptase (SSIII, Invitrogen, Carlsbad, CA) with Universal_F primer: 5' GACTAATACGACTCACTATAGGGAGCAAAAGCAGG 3'. cDNA synthesis was performed in a reaction containing 10 μl of isolated viral RNA, 1.6 μM of Universal_F primer, 600 units of SSIII, 0.5 mM dNTPs, 50 mM DTT, and first strand buffer in a total volume of 50 μl. The reaction mixture was incubated at 55°C for two hours, followed by SSIII inactivation at 70°C for 20 min.

Two different PCR protocols were used to simultaneously amplify all genome segments of influenza virus.

Phusion protocol: Four microliters of viral cDNA was used as a template for PCR amplification in a total reaction volume of 50 μl, containing 0.2 μM of each universal primers: Universal_F (see above) and Universal_R: 5'GACATTTAGGTGACACTATAGAAGTAGAAACAAGG 3', 200 μM of dNTP, 3 mM MgCl~2~, and 1 unit of Phusion DNA polymerase (New England BioLabs, Ipswich, MA). PCR cycling conditions were as follows: an initial denaturation at 98°C for 30 sec followed by 35 cycles of 98°C for 10 sec, 55°C for 30 sec and 72°C for 5 min, and the final elongation at 72°C for 10 min.

Extensor protocol: Four microliters of viral cDNA was used as a template for PCR amplification in a total reaction volume of 50 μl containing 0.4 μM of each universal primer (Universal_F and Universal_R), 500 μM of dNTP, 5 μl of 10x Extensor Buffer 2, and 2.5 units of Extensor PCR Enzyme Mix (5U/μl) (Dharmacon, Lafayette, CO). PCR cycling conditions were as follows: an initial denaturation at 94°C for 2 min followed by 35 cycles of 94°C for 10 sec, 60°C for 30 sec and 68°C for 5 min, and the final elongation at 68°C for 10 min.

The resulting eight DNA amplicons representing all segments of viral genome were separated by electrophoresis in 1% agarose gels with ethidium bromide (Lonza, Rockland, ME) and visualized using the Kodak Gel Logic 200 Imaging System and Kodak Molecular Imaging Software (Carestream Health, Inc. Rochester, NY).

Preparation of samples for Illumina sequencing {#sec004}
----------------------------------------------

The PCR product was purified by QIAquick PCR Purification Kit (Qiagen, Valencia, CA) and fragmented by focused ultrasonicator (Covaris) to generate the optimal fragment sizes of 350--400 bp suitable for Illumina sequencing.

The DNA fragments were analyzed for DNA size by the 2100 Bioanalyzer system using a high-sensitivity kit (Agilent Technologies, Inc., Santa Clara, CA). Next, the fragmented DNAs were used for library preparation with NEBNext^®^ DNA Sample Prep Reagent Set 1 (New England BioLabs, Ipswich, MA). The primers containing multiplexing index adapters (barcodes) to identify sequencing reads belonging to each sample were synthesized according to the specifications provided by Illumina Inc. for multiplex pair-end sequencing. Deep sequencing was performed at Macrogen (Seoul, Korea) using HiSeq2000 (Illumina) producing 101 bp-long paired-end reads, or at our laboratory using MiSeq (Illumina) producing 100 to 300 bp-long paired-end reads.

NEBNext mRNA Sample Prep Master Mix Set 1 (New England BioLabs, Ipswich, MA) was used for preparation of Illumina sequencing libraries from total RNA contained in the sample (whole-RNA library). Briefly, 0.5 μg total RNA (extracted as mentioned above) was used for fragmentation by focused ultrasonicator (Covaris) to generate the optimal fragment sizes of 200--300 bp suitable for RNA Illumina sequencing. The fragmented RNA was used for cDNA synthesis using ProtoScript II Reverse Transcriptase and random primers. The cDNA was further converted into double stranded cDNA with end-repair procedure (Klenow fragment, T4 polynucleotide kinase and T4 polymerase), and ligated to Illumina paired end (PE) adaptors. Size selection was performed using 2% agarose gel electrophoresis, generating cDNA libraries ranging from 275 to 325 bp in size. Finally, the libraries were expanded using 15 cycles of PCR with multiplex indexed primers and purified with magnetic beads using Agencourt Ampure Beads (Beckman Coulter).

Data analysis {#sec005}
-------------

Reference RNA sequences of X-179A, X-181, 121XP, A/California/07/2009 (H1N1), and A/PR/08/34 viruses were downloaded from GenBank. Accession numbers for segments 1 to 8 of X-179A were CY058516 to CY058523 respectively. The same sequence references were used for X-181 except for segments 2, 4, and 6 were replaced by GQ906800---GQ906802 respectively. For 121XP virus, the reference sequences for segments 1 to 8 were GQ454863, GQ454864, GQ454865, GQ280121, GQ454866, GQ280122, GQ454867, and GQ454868 respectively. As references for A/PR/8/34 viruses, we used the sequences downloaded from GenBank; for segments 1--7 the accession numbers were EF467818- EF467824 respectively and EF467817 for segment 8. For A/California/07/2009 (H1N1) the following NCBI sequences were used for segments 1 to 8: CY121687, CY121686, CY121685, CY121680, CY121683, CY121682, CY121681, and CY121684 respectively.

The RNA sequences were used as references for alignment of the viral sequence reads generated in this study. First, sequencing reads with low quality (phred) scores were removed from the data set. The remaining sequences aligned with reference influenza virus sequences using custom software that is implemented in a highly integrated virtual environment (HIVE) computer cluster (<https://hive.biochemistry.gwu.edu/dna.cgi?cmd=main>).

To eliminate the false mutations, which could be an artifact produced during PCR amplification or sequencing procedures, the bias mutations were identified by Shannon entropy as a measure of randomness of distribution of mutations along individual sequencing reads \[[@pone.0138650.ref027]\]. Generally, a bias of mutation is considered significant if its entropy value is lower than one sigma (≈0.67). Also, only sequencing reads that have more than 75% of their expected size were aligned to the reference sequences, to eliminate nonspecific reads.

Finally, aligned sequencing reads were used to compute single-nucleotide polymorphism (SNP) profiles, read depth and the entropy for the entire viral genomes.

Results {#sec006}
=======

Robustness of simultaneous influenza A genome segment amplification {#sec007}
-------------------------------------------------------------------

To amplify all segments in one reaction, the reverse transcriptase Superscript III was used for cDNA synthesis, and two different PCR amplification protocols were used for DNA amplification.

The agarose gel electrophoresis results showed that all eight segments were amplified efficiently from passaged A/California/07/2009 (H1N1) pandemic vaccine viruses (The used viruses are presented in [Table 1](#pone.0138650.t001){ref-type="table"}) by using Phusion DNA polymerase (New England BioLabs, Ipswich, MA) ([Fig 1A](#pone.0138650.g001){ref-type="fig"}). In contrast, use of Thermo Scientific Extensor Mix resulted in nonspecific bands and poor amplification of some segments ([Fig 1B](#pone.0138650.g001){ref-type="fig"}). To determine which of the two PCR protocols ensured unbiased amplification of all segments of influenza virus genome, the amplified samples ([Fig 1A and 1B](#pone.0138650.g001){ref-type="fig"}) were subjected to Illumina HiSeq sequencing. The percentage of sequencing reads obtained for each of the segments is presented in [Fig 1C](#pone.0138650.g001){ref-type="fig"}, along with the whole-RNA library that was run by HiSeq that was prepared as described in section 2.3 of the materials and methods paragraph. This result demonstrated that adequate distribution of sequencing reads between segments were obtained from a DNA library prepared from samples amplified by Phusion DNA polymerase (DNA library), and by whole-RNA library.

![A: Simultaneous RT-PCR amplification of the eight segments of A/California/07/2009 (H1N1) vaccine viruses using Phusion DNA polymerase, 1: 1 kb DNA Ladder, 2: X-181-M1, 3: X-179A-M1, 4: X-181-M2, 5: X-179A-M2, 6: X-181-M3, 7: X-179A-M4, 8: 1 kb DNA Ladder, 9: 1 kb DNA Ladder, 10: 121XP-M4, 11: X-181-M4, 12: X-179A-M3, 13: X-179A-M5, 14: X-179A, 15: X-181, 16: Negative control (H~2~O). B: Simultaneous RT-PCR amplification of the eight segments of A/California/07/2009 (H1N1) vaccine viruses using Thermo Scientist Extensor Mix, 1: 1 kb DNA Ladder, 2: X-181-M1, 3: X-179A-M1, 4: X-181-M2, 5: X-179A-M2, 6: X-181-M3, 7: X-179A-M4, 8: Negative control (H~2~O), 9: 1 kb DNA Ladder, 10: 121XP-M4, 11: X-181-M4, 12: X-179A-M3, 13: X-179A-M5, 14: X-179A, 15: X-181, 16: Negative control (H~2~O). C: The distribution amount of sequencing reads between the eight segments of influenza virus using different approaches of library preparation followed by Illumina HiSeq sequencing.](pone.0138650.g001){#pone.0138650.g001}

Consistency of Illumina sequencing, and sequencing analysis of A/PR/8/34 and A/California/07/2009 strains {#sec008}
---------------------------------------------------------------------------------------------------------

Center for Biologics Evaluation and Research (CBER) stock of A/PR/8/34 was kindly provided by Dr. Peter Palese at Mount. Sinai School of Medicine and was passaged in CBER to produce CBER stock, this virus was sequenced five times by MiSeq and HiSeq using whole-RNA library and DNA library approaches. The results of sequencing the RNA library showed high levels of reproducibility. There was a slight difference between MiSeq and HiSeq results only for mutations present at low levels (around 5%, [Table 2](#pone.0138650.t002){ref-type="table"}). In contrast, the five repeats of DNA library sequencing were less consistent and more heterogeneous. ([S1 Table](#pone.0138650.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0138650.t002

###### Percentage of mutations (≥5%) emerged in the genome of A/PR/8/34 strain (CBER stock) obtained by sequencing five times its RNA library by HiSeq and MiSeq.

Notes: MiSeq values that differ from HiSeq\'s values are presented in parentheses. These mutation percentages were calculated per comparison to their published sequences. (See accession numbers in [Materials and Methods](#sec002){ref-type="sec"} paragraph.) nt: Nucleotide, aa: Amino-acid.

![](pone.0138650.t002){#pone.0138650.t002g}

  Segment   nt. Change   aa. Change        A-PR8-34 Repeat 1   A-PR8-34 Repeat 2   A-PR8-34 Repeat 3   A-PR8-34 Repeat 4   A-PR8-34 Repeat 5
  --------- ------------ ----------------- ------------------- ------------------- ------------------- ------------------- -------------------
  PB2       279C→A       Silent (84Ala)    100                 100                 100                 100                 100
            306A→T       Silent (93Pro)    100                 100                 100                 100                 100
            1422C→A      Silent (465Pro)   100                 100                 100                 100                 100
            2127G→A      Silent (700Glu)   99                  99                  99                  98                  98
            2128A→G      701Asn→Asp        99                  99                  99                  98                  98
  PB1       294G→A       Silent (90Glu)    100                 100                 100                 100                 100
            297G→A       Silent (91Ala)    100                 100                 100                 100                 100
            370C→A       116Gln→Lys                                                                    6 (\<5)             5(\<5)
            639G→A       205Met→Ile        100                 100                 100                 100                 100
            1002C→A      Silent (326Thr)   100                 100                 100                 100                 100
            1204T→C      394Ser→Pro        99                  99                  99                  99                  99
            1551T→C      Silent (509Leu)   99                  99                  99                  99                  99
            2076G→A      Silent (684Glu)   100                 100                 100                 100                 100
  PA        323C→A       100Ala→Asp        5 (\<5)             6 (\<5)             5(\<5)              6 (\<5)             6(\<5)
            323C→G       100Ala→Gly        5 (\<5)             5(\<5)              5(\<5)              6 (\<5)             6(\<5)
            799C→A       259Pro→Thr        8 (5)               8 (6)               7 (5)                                    
            873A→G       Silent (283Leu)   100                 100                 100                 100                 100
            1233T→A      Silent (403Leu)   100                 100                 100                 100                 100
            2151A→C      Silent(709Ser)    99                  99                  99                  99                  99
  HA        60T→A        10Cys→Ser         100                 100                 100                 100                 100
            1042A→C      337Asn→Thr        99(100)             99(100)             99                  99(100)             99(100)
  NP        54T→C        Silent(3Ser)      99(100)             99(100)             99                  99(100)             99(100)
            69A→G        Silent(8Arg)      100                 100                 100                 100                 100
            282T→G       Silent (79Leu)    100                 100                 100                 100                 100
            630A→G       Silent (195Arg)   100                 100                 100                 100                 100
            924G→A       Silent (293Arg)   100                 100                 100                 100                 100
            1094C→A      350Thr→Lys        22 (18)             22 (18)             21 (18)             20 (18)             22 (18)
            1350G→A      Silent(435Gly)    100                 100                 100                 100                 100
  NA        43T→C        8Ile→Thr          97                  97                  97                  96                  96
            258C→A       80Arg→Ser                                                                     5(\<5)              5(\<5)
            314C→A       98Asp→Glu         6 (\<5)             6 (\<5)             6 (\<5)             7(\<5)              7(\<5)
            412G→A       131Ser→Asn        100                 100                 100                 100                 100
            773G→A       Silent(251Ser)    100                 100                 100                 100                 100
            860T→C       Silent(280Asn)    98 (99)             98(99)              98(99)              98(99)              98(99)
            1142G→T      Silent(374Val)    100                 100                 100                 100                 100
            1211G→A      Silent (397Leu)   100                 100                 100                 100                 100
            1357C→A      446Ala→Asp                                                5(\<5)              5(\<5)              5(\<5)
  M         67C→A        Silent (14Ile)    9(\<5)              9(\<5)              9(\<5)              9(\<5)              9(\<5)
            136C→T       Silent (37Thr)    100                 100                 100                 99%                 100
            685A→G       Silent (220Gly)   100                 100                 100                 100                 100
            697C→A       224Ser→Arg        6 \<5)              6 (\<5)             7(\<5)              6 (\<5)             6 (\<5)
            792A→G       5\'UTR            100                 99                  99                  99                  99
  NS        105C→A       27Leu→Ile         6 (\<5)             6 (\<5)             6 (\<5)             7(\<5)              6 (\<5)
            170T→C       Silent (48Ser)    100                 100                 100                 100                 100
            173T→C       Silent (49Thr)    100                 100                 99                  100                 100
            189A→G       55Lys→Glu         100                 100                 100                 100                 99(100)
            575A→G       Silent (183Gly)   100                 100                 100                 100                 100

Most of A/PR/8/34 segments contained several complete mutations in comparison to their published sequences, and most of these mutations were silent. This virus was less heterogeneous, as few low substitutions were observed along the genome.

Another A/PR/8/34 virus stock was provided by National Institute for Biological Standards and Control (NIBSC) and was propagated 13 times in eggs and then was grown (passage 14) separately in two different eggs, and the resulting stocks were designated as A/PR/8/34-1 and A/PR/8/34-3 ([Table 1](#pone.0138650.t001){ref-type="table"}). Both of them were used for whole-RNA library preparation, followed by HiSeq sequencing. The results in [Table 3](#pone.0138650.t003){ref-type="table"} showed that these two viruses shared almost all mutations, and the percentages of mutations were slightly higher in the A/PR/8/34-1 than in the A/PR/8/34-3 virus. They were more heterogeneous than CBER A/PR/8/34 virus stock, and all three A/PR/8/34 viruses shared several complete mutations along their genomes (Tables [2](#pone.0138650.t002){ref-type="table"} and [3](#pone.0138650.t003){ref-type="table"}). They also shared one low-level mutation C~1094~A (Thr~350~Lys) in the NP gene which was present in about 20% of the RNA sequences in all three A/PR/8/34 viruses.

10.1371/journal.pone.0138650.t003

###### Percentage of mutations (≥5%) emerged in A/PR/8/34 viruses 1 and 3 genomes that were subjected to RNA library preparation followed by HiSeq sequencing.

Note: These mutation percentages were calculated per comparison of A/PR/8/34 strains 1 and 3 genomes with the corresponding published sequences. (See accession numbers in [Materials and Methods](#sec002){ref-type="sec"} paragraph.) nt: Nucleotide, aa: Amino-acid.
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  Segment   nt. Change   aa. change        A/PR/8/34-1   A/PR/8/34-3
  --------- ------------ ----------------- ------------- -------------
  PB2       51A→G        Silent (8Arg)     28            12
            130A→C       35Thr→Pro         15            
            133T→G       36Ser→Ala         17            5
            139A→T       38Arg→Stp         6             
            142C→A       39Gln→Lys         6             5
            1083G→A      Silent (352Leu)   5             
            1306C→A      Silent(427Arg)                  6
            2128A→G      701Asn→Asp        99            99
            2142G→C      Silent(705Gly)                  6
            2149C→T      Silent (708Leu)   10            
            2199G→A      Silent (724Val)   15            6
            2238G→A      Silent (737Arg)   36            14
            2243G→A      739Arg→Gln        23            9
  PB1       115A→T       31Ser→Cys         10            5
            133G→A       37Gly→Arg         20            10
            179A→G       52Lys→Arg         18            9
            189G→A       55Trp→Stp         19            11
            192A→T       Silent (56Thr)    13            7
            370C→A       116Gln→Lys                      6
            2076G→A      Silent (684Glu)   33            16
            2097G→A      Silent (691Arg)   37            19
            2145A→G      Silent (707Arg)   40            21
            2178G→A      718Met→Ile        36            18
            2179G→T      719Val→Phe        35            16
            2236G→A      738Glu→Lys        46            23
            2267C→A      748Ser→Tyr        6             7
  PA        150G→A       Silent (42Leu)    6             
            323C→A       100Ala→Asp        7             8
            323C→G       100Ala→Gly        7             8
            873A→G       Silent (283Leu)   99            99
            903G→A       Silent (293Glu)   5             5
            2151A→C      Silent (709Ser)   99            98
  HA        724C→A       231Ala→Glu                      5
            1042A→T      337Asn→Ile        100           100
            1052T→C      Silent (340Ile)   9             5
            1413C→A      461Leu→Met        5             5
  NP        132C→T       Silent (29Val)    8             
            184C→A       47Leu→Ile                       6
            1094C→A      350Thr→Lys        19            22
  NA        258C→A       80Arg→Ser         5             6
            304C→A       95Ser→Tyr                       6
            773G→A       Silent (251Ser)   100           100
            1357C→A      446Ala→Asp        7             6
  M         58A→T        Silent (11Val)    23            9
            67C→A        Silent (14Ile)    6             9
            100A→G       Silent (25Ala)    24            11
            113G→A       30Asp→Asn         28            11
            130G→A       Silent (35Lys)    30            13
            240G→A       72Arg→Gln         26            10
            241A→G       Silent (72Arg)    29            11
            334C→T       Silent (103Leu)   27            11
            353C→T       110His→Tyr        25            10
            361C→T       Silent (112Ala)   29            11
            370C→A       Silent (115Ile)   26            11
            371T→G       116Ser→Ala        25            11
            385T→C       Silent (120Ser)   22            9
            401A→T       126Ser→Cys        25            9
            434G→A       137Ala→Thr        23            10
            442C→T       Silent(139Thr)    25            9
            443A→G       140Thr→Ala        28            10
            453C→T       143Ala→Val        22            8
            454A→G       Silent (143Ala)   23            10
            524A→G       167Thr→Ala        26            12
            643T→G       Silent (206Ala)   23            10
            645G→T       207Ser→Ile        22            9
            648A→G       208Gln→Arg        25            10
            655A→G       Silent (210Arg)   27            11
            667A→G       Silent (214Gln)   27            11
            670G→A       Silent (215Ala)   29            12
            685A→G       Silent (220Gly)   100           100
            697C→A       224Ser→Arg        7             8
            716A→G       231Asn→Asp        24            10
            792A→G       5\'UTR            31            11
            793C→T       5\'UTR            22            9
            801G→T       5\'UTR            29            11
            805A→G       5\'UTR            26            10
            829C→T       5\'UTR            22            9
            874G→T       5\'UTR            27            9
            887A→T       5\'UTR            27            12
            888C→T       5\'UTR            25            9
            894G→A       5\'UTR            26            10
            943G→A       5\'UTR            31            12
  NS        591G→A       189Asp→Asn        6             7
            616C→A       197Thr→Asn                      6

A/California/07/2009 (H1N1) strain was sequenced by HiSeq using the whole-RNA library approach, and the summary of the results is presented in [Table 4](#pone.0138650.t004){ref-type="table"}. No complete substitutions were observed, and the highest percentage of mutants observed was 66% for mutation A~57~G (Glu~18~Gly) in the PA segment. No mutations were observed in the NA segment. Three low-level non-synonymous mutations were found in HA: A~456~G (Asn~146~Asp, 11%), A~736~G (Asp~239~Gly, 16%) and G~739~A (Arg~240~Gln, 16%). The Asn~146~Asp mutation is located in the Sa antigenic site.

10.1371/journal.pone.0138650.t004

###### HiSeq sequencing of RNA Library prepared from A/Ca/07/2009 (H1N1) virus.

Note: These mutation percentages were calculated per comparison of A/California/07/2009 (H1N1) genome with its published sequence. (See accession numbers in [Materials and Methods](#sec002){ref-type="sec"} paragraph.) aa: Amino acid, nt: Nucleotide.
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  Segment   nt. Change[\*](#t004fn001){ref-type="table-fn"}   aa. Change        Mutation percent (≥5%)
  --------- ------------------------------------------------- ----------------- ------------------------
  PB2       114G→T                                            33Lys→Asn         7
            125G→C                                            37Gly→Ala         5
            129G→A                                            Silent (38Arg)    5
            1726C→T                                           Silent (571Leu)   46
  PA        57A→G                                             18Glu→Gly         66
            121C→A                                            39Cys→Stp         7
  HA        456A→G                                            146Asn→Asp        11
            736A→G                                            239Asp→Gly        16
            739G→A                                            240Arg→Gln        16
  NP        335G→A                                            101Gly→Asp        31
            337G→A                                            102Gly→Arg        5
            357C→T                                            Silent (108Leu)   6
            374A→G                                            114Glu→Gly        6
            1156G→A                                           375Asp→Asn        15

\*: Count of nucleotide location started 20 nucleotides (UTR) before the starting codon AUG.

3.3. Deep sequencing analysis of 121XP virus passaged in eggs {#sec009}
-------------------------------------------------------------

The 121XP virus was generated by the reverse genetics method followed by serial passages in chicken eggs; this virus contains the HA and NA genes from A/California/07/2009 (H1N1) and all other genes from A/PR/8/34 (H1N1) \[[@pone.0138650.ref026]\].

To evaluate its genetic stability, the 121XP virus was passaged ten times in eggs under manufacture conditions ([Table 1](#pone.0138650.t001){ref-type="table"}). Mutations revealed by deep sequencing in HA and NA genes of the virus are summarized in [Table 5](#pone.0138650.t005){ref-type="table"}. Several non-synonymous mutations emerged in NA and HA, including the mutations Asn~16~Ser and Lys~226~Glu that were present at low levels (36% and 18% of mutants, respectively). The latter mutation is located in the Ca antigenic site in HA. Mutation Lys~136~Asn, located close to the antigenic site Sa, emerged and accumulated to about 78% of the population.

10.1371/journal.pone.0138650.t005

###### Mutation percentages (≥5%) emerged in HA and NA of 121XP-M4 virus passaged in eggs.

Note: These mutation percentages were calculated per comparison with the corresponding expanded wild-type progenitor. (See accession numbers in [Materials and Methods](#sec002){ref-type="sec"}.) aa: Amino-acid, nt: Nucleotide.
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  Segment   nt. Change   aa. Change        HiSeq   MiSeq   
  --------- ------------ ----------------- ------- ------- -----
  HA        47A→G        16Asn→Ser         32      36      33
            338T→C       113Ile→Thr        7       7       7
            408G→T       136Lys→Asn        79      78      78
            561G→A       Silent (187Gly)   9       10      9
            676A→G       226Lys→Glu        15      18      16
  NA        166T→C       56Tyr→His         14      17      17
            248T→C       83Val→Leu         14      13      16
            255A→G       85Leu→Val         84      83      82
            262A→G       88Asn→Asp         83      81      80
            263A→G       88Asn→Asp         84      83      81
            264T→C       88Asn→His         14      17      19
            355A→G       119Lys→Glu        100     100     100
            708T→G       Silent (236Gly)   37      37      38
            1352A→G      Silent (451Asp)   35      42      38
            1354A→G      452Thr→Ala        35      47      39

Ten mutations were found in the NA gene, and eight of them led to amino acid changes. Interestingly, three of them were found in codon 88. Sequencing of other genomic segments revealed several heterogeneities in most of them, with some mutations leading to amino acid changes. There was a good agreement between results obtained by sequencing of the whole-RNA library by MiSeq and HiSeq, as well as the DNA library by HiSeq. For more details, see [S2](#pone.0138650.s002){ref-type="supplementary-material"} to [S5](#pone.0138650.s005){ref-type="supplementary-material"} Tables.

Deep sequencing analysis of X-179A viruses passaged in eggs {#sec010}
-----------------------------------------------------------

The X-179A virus is a reassortant prepared by New York Medical College (NYMC) using classical reassortant methodology from A/California/7/2009 (H1N1) virus and NYMC X-157 virus, with the HA, NA and PB1 genes originating from A/California/7/2009 (H1N1), and the other internal genes from A/PR/8/34 (H1N1) \[[@pone.0138650.ref026]\]. This virus was passaged several times and adapted to grow in eggs. Viruses derived by passaging of X-179A virus in chicken eggs under manufacture conditions ([Table 1](#pone.0138650.t001){ref-type="table"}) were similarly analyzed by deep sequencing. The results of deep sequencing of HA and NA genes of these viruses are summarized in [Table 6](#pone.0138650.t006){ref-type="table"}. In sample X-179A-M5, two non-synonymous mutations emerged in HA: Pro~314~Gln (17%) and Asn~146~Asp (78%). The latter mutation located in the Sa antigenic site was present as low level mutation in A/California/07/2009 (H1N1). The confirmation of the presence of this mutation by Sanger sequencing method is presented on [Fig 2](#pone.0138650.g002){ref-type="fig"}. Sample X-179A-M2 contained a low level (9%) of Lys~328~Thr mutation.

![Sanger sequencing of the presence of mutation Asn~146~Asp (A~436~G) that was detected by Illumina sequencing at diffent levels: 11% in A/Ca/07/2009 (H1N1) virus, 78% in X-179A-M5 virus and 92% in X-181 virus.](pone.0138650.g002){#pone.0138650.g002}

10.1371/journal.pone.0138650.t006

###### Mutation percentages (≥5%) emerged in HA and NA of X-179A viruses passaged in eggs.

Notes: The percentages obtained from RNA library followed by HiSeq sequencing are presented without parentheses or brackets. The percentages obtained from RNA library followed by MiSeq sequencing are presented in parentheses. The percentages obtained from DNA library followed by HiSeq sequencing are presented in brackets. These mutation percentages were calculated per comparison with the corresponding expanded progenitor. (See accession numbers in [Materials and Methods](#sec002){ref-type="sec"}.) aa: Amino-acid, nt: Nucleotide.
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  Segment   nt. Change   aa change    X-179A                       X179A-M1   X-179A-M2   X-179A-M3                        X-179A-M4   X-179A-M5
  --------- ------------ ------------ ---------------------------- ---------- ----------- -------------------------------- ----------- -----------------------------------
  HA        436A→G       146Asn→Asp                                                                                                    78 (82) \[80\]
            941C→A       314Pro→Gln                                                                                                    17 (16)\[[@pone.0138650.ref016]\]
            983A→C       328Lys→Thr                                           9(8)\[8\]                                                 
  NA        284G→T       95Ser→Ile                                                        7(7)\[[@pone.0138650.ref007]\]                
            911T→G       304Val→Gly   \[[@pone.0138650.ref005]\]                                                                        

One non-synonymous mutation, Ser~95~Ile, was present at a low level (7%) in NA of sample X179A-M3.

In general, samples derived from X-179A virus were heterogeneous and contained several complete substitutions compared to its published sequence.

HiSeq sequencing of DNA libraries prepared from X-179A viruses revealed more heterogeneity than HiSeq/MiSeq sequencing of RNA libraries prepared from the same samples. Mutations found in other genomic segments are presented in [S5](#pone.0138650.s005){ref-type="supplementary-material"} to [S7](#pone.0138650.s007){ref-type="supplementary-material"} Tables.

Deep sequencing analysis of X-181 viruses passaged in eggs {#sec011}
----------------------------------------------------------

Similar to X-179A virus, X‐181 virus was developed by New York Medical College using conventional reassortment technology. It has a 5:3 gene constellation with three genes (PB1, HA and NA) coming from A/California/07/2009 (H1N1) and the remaining five genes from A/PR/8/34 \[[@pone.0138650.ref026]\]. The A/PR/8/34 genes were provided by reassorting NYMC X‐157 with A/California/07/2009 (H1N1). This virus is produced to grow well in eggs, and was passaged several times in eggs.

Viruses derived by passaging of the X-181 virus in chicken eggs under manufacture conditions ([Table 1](#pone.0138650.t001){ref-type="table"}) were analyzed by deep sequencing. The results of deep sequencing of HA and NA genes of these viruses are summarized in [Table 7](#pone.0138650.t007){ref-type="table"}. Two mutations were found in HA genes: A~1398~G (silent, 31%) in the X-181-M3 virus and G~756~T (Glu~252~Asp, 47%) in the X-181-M4 virus. The latter mutation is located in the conserved region of the antigenic site Ca. One non-synonymous mutation, Thr~466~Ala, was present at a low level (8%) in the NA gene of X-181-M2. Interestingly, the mutation Asn~146~Asp is located in the Sa antigenic site and exists as a complete substitution in X-181 virus which is derived from X-179A virus. As mentioned above, this mutation was observed in X-179A-M5 at a high level (78%) and at a low level (11%) in the wild-type A/California/07/2009 (H1N1) virus.

10.1371/journal.pone.0138650.t007

###### Mutation percentages (≥5%) emerged in HA and NA of X-181 viruses passaged in eggs.

Notes: The percentages obtained from RNA library followed by HiSeq sequencing are presented without parentheses or brackets. The percentages obtained from RNA library followed by MiSeq sequencing are presented in parentheses. The percentages obtained from DNA library followed by HiSeq sequencing are presented in brackets. These mutation percentages were calculated per comparison with the corresponding expanded progenitor. (See accession numbers in [Materials and Methods](#sec002){ref-type="sec"}.) aa: Amino-acid, nt: Nucleotide.
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  Segment   nt. change   aa. Change       X-181   X-181-M1   X-181-M2     X-181-M3       X-181-M4
  --------- ------------ ---------------- ------- ---------- ------------ -------------- --------------
  HA        436G→A       146Asp→Asn       \(8\)                                           
            756G→T       252Glu→Asp                                                      47(46)\[46\]
            1398A→G      Silent(466Val)                                   31(31)\[29\]    
  NA        465T→C       Silent(155Tyr)                                   5               
            911T→G       304Val→Gly       \[7\]                                           
            1396A→G      466Thr→Ala                          20(6)\[8\]                   

Viruses derived by passaging of X-181 in chicken eggs were heterogeneous and contained several complete mutations in PB2, NP and NS segments ([S8](#pone.0138650.s008){ref-type="supplementary-material"} to [S10](#pone.0138650.s010){ref-type="supplementary-material"} Tables).

As for X-179A viruses, HiSeq sequencing of DNA libraries prepared from X-181 viruses revealed more heterogeneity than HiSeq/MiSeq sequencing of whole-RNA libraries prepared from the same samples. Mutations found in other genomic segments are presented in [S8](#pone.0138650.s008){ref-type="supplementary-material"} to [S10](#pone.0138650.s010){ref-type="supplementary-material"} Tables.

Discussion {#sec012}
==========

Rapid emergence of mutations is an inherent property of RNA viruses, leading to genetic heterogeneity of viral populations \[[@pone.0138650.ref008]\]. This allows viruses to rapidly adapt to changing growth conditions by selecting from the preexisting variants with higher fitness \[[@pone.0138650.ref028]\]. For some vaccines, virus growth in cell cultures during vaccine manufacture leads to reversion of attenuated phenotype to virulence; therefore, their content must be monitored as a part of vaccine quality control \[[@pone.0138650.ref013]\]. Mutations emerging during virus growth may also alter the antigenic properties, and as a consequence affect protective potency of live and inactivated vaccines. Antigenic properties of influenza A are notoriously prone to rapid changes. Hemagglutinin (HA) and neuraminidase (NA) are the two most important influenza virus envelope proteins that elicit immune response, and therefore are under immunological pressure that leads to their continuous change. The antigenic drift reflects the accumulation of amino acid substitutions in the globular domain of HA, the principal target of neutralizing antibodies, as well as in NA \[[@pone.0138650.ref029], [@pone.0138650.ref030]\]. The primary function of HA is the attachment to host cell receptors and mediation of viral entry \[[@pone.0138650.ref031], [@pone.0138650.ref032]\]. The NA is involved in progeny virion release and spread of the virus, and also may have a role in HA-mediated membrane fusion \[[@pone.0138650.ref033], [@pone.0138650.ref034]\]. Adaptation of viruses to replication in new cell types (e.g. growth in cell substrates, such as embryonated eggs or mammalian cells used for vaccine manufacture) involves changes in HA. Since the receptor-binding region on the HA molecule overlaps with the major antigenic site, the adaptation may also be accompanied by changes in antigenic properties \[[@pone.0138650.ref033], [@pone.0138650.ref035], [@pone.0138650.ref036]\].

The larger number of eggs used during manufacture process would decrease the level (percentage) of each individual mutant, but could nevertheless increase the overall heterogeneity of virus population. Cumulatively, they could lead to a similar loss of antigenic properties as one mutation present at a higher level. Therefore, it may be important to monitor the changes that take place in major protective epitopes of the seed virus stocks to avoid losses in protective efficacy of the vaccine. Not all mutations that emerge in viruses are harmful to vaccine properties. Mutations that consistently accumulate have higher fitness and could increase virus yields and vaccine potency. Therefore, studying mutations emerging in vaccine strains could be used for both quality control, and for optimization of the genetic composition of vaccine strains.

Seed viruses used in influenza vaccine manufacture are produced either by reassortment technology that uses co-cultivation of a high-growth reference strain with the current virus isolate leading to exchange of genomic segments \[[@pone.0138650.ref037]\], or by reverse genetics based on transfection of susceptible cells with a combination of cDNA plasmids coding for the appropriate segments of the virus \[[@pone.0138650.ref038]\]. Both approaches have their strengths and weaknesses, and can potentially lead to the emergence of mutants. One of the purposes of this study was to determine which of them produces more homogeneous virus stocks with a lower number of mutants. We have used three pandemic influenza A/California/07/2009 (H1N1) virus vaccine strains and virus stocks produced from these viruses by passaging them on eggs. X-179A was prepared at the New York Medical College on eggs as a reassortant between A/California/07/2009 and A/PR/8/34. After reports of a low yield of production virus from X-179A a second reassortant, X-181, was made. X-181 contains the HA, NA and PB1 segments from A/California/07/2009. 121XP was made using reverse genetics followed by serial passages in eggs and only has the HA and NA segments from A/California/07/2009 virus \[[@pone.0138650.ref026]\].

To reveal sequence heterogeneity in viral stocks we have used a deep sequencing approach that was recently shown to be an effective tool for quantifying all mutants in viral populations \[[@pone.0138650.ref024]\]. Mutations that were identified by deep sequencing and were present at a significant level were also confirmed by the analysis of Sanger sequencing electrophoregrams that revealed sequence heterogeneities. Amplification of the entire genome of influenza viruses presents a challenge because it consists of eight genomic segments of different lengths and sequences. Previously, we described PCR conditions that allowed us to amplify all genomic segments of influenza A virus in one reaction \[[@pone.0138650.ref027]\]. In this work, the PCR amplification was optimized to amplify all influenza segments simultaneously, efficiently and equally, which resulted in an adequate distribution of sequencing reads between all segments ([Fig 1A and 1C](#pone.0138650.g001){ref-type="fig"}). We have also used whole-RNA libraries prepared without specific amplification of viral cDNA. Illumina deep-sequencing of viral cDNA libraries and whole-RNA libraries were used to determine quantitative profiles of mutations along the entire genome of viruses of influenza A/California/07/2009 (H1N1) vaccines.

The deep sequencing results revealed several heterogeneities in most genomic segments, and several mutations led to amino acid changes. No big differences were observed between the results obtained by sequencing of whole-RNA libraries using MiSeq and HiSeq, and HiSeq sequencing of DNA libraries ([S2](#pone.0138650.s002){ref-type="supplementary-material"} to [S10](#pone.0138650.s010){ref-type="supplementary-material"} Tables). Deep sequencing of whole-RNA libraries was found to be more reproducible than sequencing of DNA libraries ([Table 2](#pone.0138650.t002){ref-type="table"}). But the HiSeq sequencing of DNA libraries were less consistent and produced more heterogeneous sequences ([S1 Table](#pone.0138650.s001){ref-type="supplementary-material"}). This may be due to errors introduced by PCR amplification and non-specific alignment of primers.

Deep sequencing of several stocks of high-growth reference strain A/PR/8/34 revealed also some mutations and sequence heterogeneities. The CBER master stock of this strain contained several complete mutations in comparison to the published sequence, and most of these mutations were silent. There were also low levels of additional mutations. This indicates that this A/PR/8/34 virus is genetically stable, and the use of this virus as backbone for development of influenza vaccine may improve the vaccine production.

Another A/PR/8/34 virus stock was passaged 13 times on eggs and was grown (passage 14) separately in two different embryonated chicken eggs, the harvested 2 viruses (designated as A/PR/8/34-1 and A/PR/8/34-3) were deep-sequenced using HiSeq protocol. These two viruses shared most sequence heterogeneities, but the percentages of mutants were slightly different ([Table 3](#pone.0138650.t003){ref-type="table"}). Therefore, virus growth in eggs introduced some additional sequence heterogeneity, but caused no complete nucleotide substitutions.

The parental wild type A/California/07/2009 (H1N1) virus was sequenced by HiSeq using the whole RNA library ([Table 4](#pone.0138650.t004){ref-type="table"}). Its consensus matched the published nucleotide sequence. There was some sequence heterogeneity observed at select positions, reaching up to 66% (Glu~18~Gly) of the viral population, this mutation is very rare and nothing known about its biological function.

The Deep sequencing of the X-179A passaged viruses revealed several mutations in HA and NA. Two non-synonymous mutations in HA (Pro~314~Gln present at 17% and Asn~146~Asp present at 78% of the population) were identified in X-179A-M5 virus. Interestingly, the latter is located in the antigenic site Sa; it was detected at a low level (11%) in A/California/07/2009 (H1N1) strain and was present as a complete substitution in the X-181 virus stock derived from the X-179A virus ([Fig 2](#pone.0138650.g002){ref-type="fig"}), suggesting that it may be involved in the adaptation of X-181 virus. Virus X-179A-M2 contained Lys~328~Thr mutation at a low level (9%). Viruses derived from X-179A were heterogeneous and contained some complete nucleotide substitutions in comparison to their published sequences in PB2, PB1, NP, and in NS segments (see [S5](#pone.0138650.s005){ref-type="supplementary-material"} to [S7](#pone.0138650.s007){ref-type="supplementary-material"} Tables).

The X-181 virus was developed from the X-179A seed lot by another round of reassortment, and also is subjected to several passages in eggs ([Table 1](#pone.0138650.t001){ref-type="table"}). Deep sequencing results showed that the G~756~T (Glu~252~Asp, present at 47%) mutation emerged in HA of the X181-M4 virus, and it is located in the conserved region of the antigenic site Ca.

Unlike the two previous viruses, 121XP was developed by reverse genetics \[[@pone.0138650.ref026]\]. Deep sequencing of virus derived from it showed several non-synonymous mutations in NA and HA. Mutations leading to Asn~16~Ser and Lys~226~Glu amino acid substitutions emerged at relatively low levels (36% and 18% of mutants, respectively) in HA. The latter mutation was located in the Ca antigenic site in HA, next to codon 225 that was shown to participate in the modulation of HA receptor avidity/specificity \[[@pone.0138650.ref039]\]. In addition, mutation of residue 225 was found to enable H3 viruses to switch from avian to human specificity \[[@pone.0138650.ref040], [@pone.0138650.ref041]\]. Mutation Lys~136~Asn was present at a high level (78%). It is located close to the antigenic site Sa in close proximity within the sialic acid-binding pocket, suggesting its functional importance \[[@pone.0138650.ref042]\]. Interestingly, in the NA segment, three mutations occurred in codon 88, suggesting that this codon represents a hot spot. Also, the results of passages 10 showed that the overall number of mutations and sequence heterogeneities present in virus stocks derived by reverse genetics was higher than the number of mutations in virus stocks created by conventional reassortment procedure. This observation is counterintuitive, since reverse genetics is based on homogeneous cDNA plasmids coding individual viral segments. One possible explanation for increased sequence heterogeneity of cDNA-derived RNA viruses is that transcription of cDNA plasmids to rescue the virus followed by its passages to adapt to grow in chicken eggs led to higher sequence heterogeneity.

In conclusion, our deep sequencing approach based on RNA library preparation was shown to be effective and reproducible for detection of low quantities of mutants in the entire genome of influenza viruses. It revealed that the viruses derived from the three of pandemic A/Ca/07/2009 (H1N1) vaccine viruses have varying levels of sequence heterogeneities. It can be used for assessment of the quality of seed viruses, and for ensuring that they do not contain mutations that could affect immunogenic properties of the vaccine.
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